ADMA, subclinical changes and atrial fibrillation in the general population.
暂无分享,去创建一个
R. Schnabel | S. Blankenberg | B. Hoffmann | T. Zeller | P. Wild | C. Sinning | K. Lackner | T. Münzel | E. Schwedhelm | R. Böger | D. Atzler | F. Ojeda | S. Appelbaum | M. Ramuschkat | Christoph Bauer
[1] Y. Okumura,et al. Increased levels of inflammatory and extracellular matrix turnover biomarkers persist despite reverse atrial structural remodeling during the first year after atrial fibrillation ablation , 2014, Journal of Interventional Cardiac Electrophysiology.
[2] T. Chao,et al. Plasma Asymmetric Dimethylarginine and Adverse Events in Patients with Atrial Fibrillation Referred for Coronary Angiogram , 2013, PloS one.
[3] W. Bauman,et al. Acute nitric oxide synthase inhibition and cardiac conduction in persons with spinal cord injury: a short report. , 2013, Die Pharmazie.
[4] P. Sanders,et al. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. , 2013, Journal of the American College of Cardiology.
[5] Shing‐Jong Lin,et al. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. , 2012, Atherosclerosis.
[6] N. Frey,et al. The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. , 2012, Journal of cardiac failure.
[7] N. McMahon,et al. Comparison of non-invasive and implanted telemetric measurement of blood pressure and electrocardiogram in conscious beagle dogs. , 2012, Journal of pharmacological and toxicological methods.
[8] A. Goette,et al. Oxidative Stress and Microcirculatory Flow Abnormalities in the Ventricles during Atrial Fibrillation , 2012, Front. Physio..
[9] A. Melidonis,et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure , 2012, Heart.
[10] A. Goette,et al. The impact of rapid atrial pacing on ADMA and endothelial NOS. , 2012, International journal of cardiology.
[11] V. Gudnason,et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[12] Josef Coresh,et al. Chronic Kidney Disease Is Associated With the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study , 2011, Circulation.
[13] D. Levy,et al. P wave duration and risk of longitudinal atrial fibrillation in persons ≥ 60 years old (from the Framingham Heart Study). , 2011, The American journal of cardiology.
[14] Michael J Pencina,et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. , 2010, Archives of internal medicine.
[15] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[16] D. Levy,et al. Relations of Biomarkers of Distinct Pathophysiological Pathways and Atrial Fibrillation Incidence in the Community , 2010, Circulation.
[17] E. Bloemena,et al. Low arginine/asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model , 2009, Critical care medicine.
[18] E. Benjamin,et al. Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample. , 2009, Atherosclerosis.
[19] S. Hazen,et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. , 2008, European heart journal.
[20] S. Nattel,et al. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.
[21] D. Luo,et al. Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. , 2007, Canadian journal of physiology and pharmacology.
[22] E. Schwedhelm,et al. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[23] Thomas Weber,et al. Arterial wave reflections and determinants of endothelial function a hypothesis based on peripheral mode of action. , 2007, American journal of hypertension.
[24] M. Guazzi,et al. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. , 2007, European journal of pharmacology.
[25] D. Levy,et al. Pulse pressure and risk of new-onset atrial fibrillation. , 2007, JAMA.
[26] Frank Donnerstag,et al. ADMA Increases Arterial Stiffness and Decreases Cerebral Blood Flow in Humans , 2006, Stroke.
[27] T. Münzel,et al. ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.
[28] K. Channon,et al. A Myocardial Nox2 Containing NAD(P)H Oxidase Contributes to Oxidative Stress in Human Atrial Fibrillation , 2003, Circulation research.
[29] P. Vallance,et al. Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[30] J. Murabito,et al. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.
[31] H. Struijker‐Boudier,et al. Current Perspectives on Arterial Stiffness and Pulse Pressure in Hypertension and Cardiovascular Diseases , 2003, Circulation.
[32] Joao A. C. Lima,et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. , 2002 .
[33] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[34] M. Chung,et al. Ascorbate Attenuates Atrial Pacing-Induced Peroxynitrite Formation and Electrical Remodeling and Decreases the Incidence of Postoperative Atrial Fibrillation , 2001, Circulation research.
[35] D. V. Van Wagoner,et al. Impaired Myofibrillar Energetics and Oxidative Injury During Human Atrial Fibrillation , 2001, Circulation.
[36] D. Levy,et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.
[37] S. Moncada,et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.
[38] H. Crijns,et al. Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[39] I. Shapira,et al. Electromechanical impairment of human auricle and rat myocardial strip subjected to exogenous oxidative stress. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[40] Joao A. C. Lima,et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms , 2002, Nature.